Difference between revisions of "Galsky MD, et al. Clin. Cancer Res. (2014) cited as Ref 632 in DOI: 10.1038/s41392-020-0110-5 (Q9895)"
Jump to navigation
Jump to search
(Created claim: title (P93): A phase I trial of LY2510924 a CXCR4 peptide antagonist in patients with advanced cancer, #quickstatements; #temporary_batch_1590010982689) |
(Created claim: Page(s) (P105): 3581-3588, #quickstatements; #temporary_batch_1590074839150) |
||
| Property / Page(s) | |||
| + | 3581-3588 | ||
| Property / Page(s): 3581-3588 / rank | |||
| + | Normal rank | ||
Latest revision as of 15:47, 21 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Galsky MD, et al. Clin. Cancer Res. (2014) cited as Ref 632 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Galsky MD
0 references
2014
0 references
Clin. Cancer Res.
0 references
20
0 references
A phase I trial of LY2510924 a CXCR4 peptide antagonist in patients with advanced cancer (English)
0 references
3581-3588
0 references
